Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer
Clinical trial NCT02689284 · COMPLETED
Trial details
- NCT number
- NCT02689284
- Sponsor
- MacroGenics
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-01-01
- Primary completion
- 2021-01-01
- Enrollment
- 95
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.